Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: RedHill’s Opaganib Fails As Company Accelerates RHB-107 Study

Plus, New Data From Pharming, CalciMedica

Executive Summary

The Israeli biotech announced disappointing Phase II/III data for opaganib while expanding its Phase II/III RHB-107 study. Pharming unveiled promising data from a company-sponsored study, but an imbalance in an investigator-led study confounded results, while CalciMedica built on the case for its drug as a treatment for COVID-19 pneumonia.

You may also be interested in...



Stock Watch: Dam Cracks After A Trickle Of Failed Pandemic Products

Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?

Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020

Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe. 

RedHill Could Soon Seek EUA For COVID-19 Therapy

The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel